"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...

Lp (a) is a genetically driven variant of low-density lipoprotein (LDL) cholesterol, that is known to be an independent risk ...

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the ...

The oral medication muvalaplin may safely lower high levels of lipoprotein(a), also known as Lp(a), an independent, inherited ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Muvalaplin significantly lowered lipoprotein(a) levels, reducing the risk of cardiovascular events in high-risk adults.

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein (a) or Lp (a) levels in adults with high risk of cardiovascular events in a ...

Muvalaplin shows promise in lowering lipoprotein(a) levels, which are genetically determined and confer cardiovascular risk ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

An experimental oral drug called muvalaplin shows promise in reducing the cholesterol linked to heart disease in a study.

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...